Celiac Disease Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031

The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period (2024-2031). The major players across the globe are adopting different business strategies including expanding their technological advancements, geographic presence, R&D activities, new product approvals, mergers & acquisitions, partnerships, and collaborations to increase market share. Among these, technological advancements, clinical trials for drug development, and others are one of the major factors that are propelling the growth of the market.

Get Free Sample link @ https://www.omrglobal.com/request-sample/celiac-disease-market

For instance, in March 2021, ImmunogenX has announced that the CeliacShield trial was completed successfully. Histology, symptoms, serology, and gluten in urine were all assessed in this gluten challenge study. The company's CypCel diagnostic technology was also used in the experiment as a tiny intestine villous health monitor, with the medication biomarker simvastatin assessed in blood samples. in February 2020, ImmunogenX, a biotherapeutics company, has begun enrolling patients in a Phase IIb clinical trial using Latiglutenase (IMGX003) for celiac disease treatment. IMGX003 is a drink-based experimental drug that helps patients improve their quality of life by breaking down gluten in the stomach and reducing gluten-induced symptoms.

Besides, in September 2020, Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that its exclusive global collaboration agreement with Bristol Myers Squibb, a company focused on developing autoimmune disease therapeutics, has been expanded to include Anokion's lead antigen-specific drug candidate, KAN-101, for the treatment of celiac disease. Apart from it, in September 2019, GlaxoSmithKline has acquired Sitari Pharmaceuticals, the first company created through its collaboration with Avalon Ventures. Inhibitors of the TG2 enzyme are being developed by a preclinical-stage biotech company named Sitari Pharmaceuticals as therapies for celiac disease, an autoimmune digestive illness. The interest in TG2 by Sitari and GSK is based on data that the protein's enzymatic activity begins the inflammatory cascade that drives and defines the disease. Gluten, a protein present in wheat, rye, and barley, causes gastrointestinal damage and decreased nutritional absorption, which precludes celiac disease sufferers from ingesting gluten-containing foods. Thus, the major player's focus on the treatment of celiac disease is driving the growth of the global celiac disease market during the forecast period.

Full report of Celiac Disease Market available @ https://www.omrglobal.com/industry-reports/celiac-disease-market

Market Coverage

Segment Covered-
o By Treatment Type

o By Diagnostic Type

o By End-User

Regions Covered-
o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Amgen Inc., Siemens AG, and Bayer AG among others
Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?
Global Celiac Disease Market Report Segment

By Treatment Type

Vitamins and Dietary (Gluten-Free) Supplements
Steroids and Immunosuppressive Drugs
Therapeutic Vaccines
By Diagnostic Type

Serologic Test
Genetic Testing
Small-Bowel Biopsy
By End-User

Hospitals and Diagnostics Centers
Research Institutes


Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/celiac-disease-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

This release was published on openPR.